Navigation Links
ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
Date:9/23/2009

er on the milestones needed to build a strong, successful and profitable Company."

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced the ... evaluating aldoxorubicin compared to topotecan in subjects with ... relapsed or were refractory to prior chemotherapy. Aldoxorubicin ... agent, doxorubicin. CytRx has received Orphan Drug Designation ...
(Date:9/29/2014)... et SAN DIEGO , 29 ... (ci-après désignée Daiichi Sankyo) (TSE : 4568) et Ambit ... conclusion d,un accord de fusion définitif en vertu ... des actions ordinaires en circulation d,Ambit Biosciences à ... biais d,une offre publique d,achat qui sera suivie ...
(Date:9/29/2014)... , Sept. 29, 2014  Bob Pack, who lost ... called on the California Medical Association to immediately cease ... that the San Jose Mercury News called "shamelessly deceptive" ... it wants voters to believe about the measure is ... the Prop 46 requirement that doctors check ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5
(Date:9/30/2014)... OH (PRWEB) September 30, 2014 ... blades sporting the iconic pink ribbon in support of ... a popular month for businesses and non-profits to “go ... worthwhile cause. , AutoTex PINK is a woman-owned company ... wipers. They are committed to partnering with their ...
(Date:9/30/2014)... DC (PRWEB) September 30, ... **MEDIA ADVISORY** , From:        Hope ... Barnwell, 910.554.1505, abarnwell(at)hopeforthewarriors(dot)org ... Hope® Celebration , Date:        Thursday, ... Address:    The Army and Navy ...
(Date:9/30/2014)... Every New Year begins with a Resolution that will soon be ... effort, however most are out of mind in 30. Why? , ... of "spend more time with children", try something easy to do ... a reminder, daily life gets in the way and efforts to ... Goals out of sight equals goals out of mind. , ...
(Date:9/30/2014)... Miraca Life Sciences (MLS), the nation’s largest independent ... the annual meeting of the American College of Gastroenterologists ... Meeting and Postgraduate Course in Philadelphia, Pa., on October ... Sciences will be at booth 711 to share information ... research posters for ACG provide a wide range of ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Youth Town’s ... from 10 a.m. to 2 p.m. at the Youth ... of the World sponsors this family-oriented festival, which will ... the festival will feature a car show, arts and ... hayride and children’s games. Also, Lightning McQueen and Mater ...
Breaking Medicine News(10 mins):Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2Health News:Miraca Life Sciences Research Institute to Present Eight GI Pathology Research Studies at Annual Meeting of American College of Gastroenterologists 2
... A team of scientists, based in UK, have grown ... successful attempt to control the development of embryonic stem ... production of replacement tissues for treating neurodegenerative conditions like ... in heavy competition over the past few years to ...
... have hailed the results of early studies into a ... out by US doctors on an anti-depression 'pacemaker' found ... of patients.// ,The pacemaker, which is implanted ... left vagus nerve in the brain. The device was ...
... if women drink too much coffee during pregnancy can increase ... have found that caffeine may be linked to the development ... been briefly starved of oxygen. ,A research team from ... from the hippocampus, a part of the brain that is ...
... Year with a resolution to get fit are urged ... could cause damage that leads to arthritis in later ... joints in their 20s and 30s are at greater ... they get older. The Arthritis Research Campaign says that ...
... other salad goods may help reduce the risk of osteoporosis ... women, usually after the menopause. Reported researchers at the ... ,They said that 1g of onion a day ... resorption, where calcium seeps from the bones making them brittle. ...
... eradicated by 1979 and vaccination against the disease gradually ... virus remain in laboratories in the US, Russia and ... concerns that these stockpiles could be used to introduce ... at present ill-prepared to deal with a potential outbreak. ...
Cached Medicine News:Health News:Stem cell research 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: